An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial

Journal of Rheumatology

Volumn 43, Issue 9, 2016, Pages 1672-1679

  Khanna, Dinesh ^a   Albera, Carlo ^g   Fischer, Aryeh ^b   Khalidi, Nader ^h   Raghu, Ganesh ^c   Chung, Lorinda ^d   Chen, Dan ^d,e   Schiopu, Elena ^a   Tagliaferri, Margit ^e   Seibold, James R ^f   Gorina, Eduard ^e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e InterMune Inc   (Australia)

^f Scleroderma Research Consultants LLC   (United States)

^g UNIVERSITY OF TURIN   (Italy)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

Interstitial lung diseases; Pirfenidone; Safety; Scleroderma; Systemic sclerosis; Tolerability

Indexed keywords

MYCOPHENOLATE MOFETIL; PIRFENIDONE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; INTERSTITIAL LUNG DISEASE; INTESTINE OBSTRUCTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SCLERODERMA; STOMACH DISCOMFORT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; MIDDLE AGED; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PYRIDONES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84984998138     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.151322     Document Type: Article

References (34)

1. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65:2737-47.
2. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013;22:6-19.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
4. Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 2010;6:138-44.
5. Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014;66:1967-78.
6. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
7. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
8. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10:248-55.
9. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
10. Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev 2013;22:236-43.
11. Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015;41:237-48.
12. Clements PJ, Tashkin D, Roth M, Khanna D, Furst DE, Tseng CH, et al. The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofitil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheumatol 2015;67 Suppl 10:1401-2.
13. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97.
14. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002;446:177-85.
15. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000;24:477-91.
16. European Medicines Agency. Esbriet: pirfenidone. [Internet. Accessed May 30, 2016.] Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002154/human-med-001417.jsp&mid=WC0b01ac058001d124
17. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-92.
18. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
19. Genentech. Esbriet prescribing information. [Internet. Accessed May 30, 2016.] Available from: www.gene.com/download/pdf/esbriet-prescribing.pdf
20. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
21. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
22. Albera C, Bradford WZ, Costabel U, Fagan EA, Glaspole I, Glassberg MK, et al. Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) and mild restrictive disease [abstract]. Am J Respir Crit Care Med 2015;191:A1018.
23. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016;47:243-53.
24. Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011;2011:976427.
25. Savarino E, Furnari M, de Bortoli N, Martinucci I, Bodini G, Ghio M, et al. Gastrointestinal involvement in systemic sclerosis. Presse Med 2014;43:e279-91.
26. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
27. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257-63.
28. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0 (CTCAE). [Internet. Accessed May 30, 2016.] Available from: ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
29. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014;19:740-7.
30. Bae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, et al. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol 2013;31 Suppl 76:57-63.
31. Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol 2011;38:1920-4.
32. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-63.
33. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010;28 Suppl 58:S55-62.
34. Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015;17:372.